Genmab A/S (GMAB) FinancialsGMABGenmab A/S

Genmab A/S (GMAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 83.6% of total sales, equivalent to $966.00M. Other significant revenue streams include Net product sales and Collaboration revenue. Understanding this composition is critical for investors evaluating how GMAB navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Genmab A/S maintains a gross margin of 92.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 35.24%, while the net margin is 26.23%. These profitability ratios, combined with a Return on Equity (ROE) of 14.00%, provide a clear picture of how effectively GMAB converts its operational activities into shareholder value.

In the context of the broader market, GMAB competes directly with industry leaders such as GILD and ARGX. With a market capitalization of $19.63B, it holds a significant position in the sector. When comparing efficiency, GMAB's gross margin of 92.73% stands against GILD's 79.76% and ARGX's 90.43%. Such benchmarking helps identify whether Genmab A/S is trading at a premium or discount relative to its financial performance.

Genmab's total revenue for Q2 2026 was $1.155 billion, with a gross margin of 92.73%, indicating strong profitability. The company has consistently shown growth in revenue and net income, with a net income of $303 million in Q2 2026.